NorthCrest Asset Manangement LLC Buys New Holdings in Illumina, Inc. $ILMN

Key Points

• NorthCrest Asset Management LLC has acquired a new stake in Illumina, Inc., purchasing 4,871 shares valued at approximately $491,000 during the second quarter.
• Illumina's stock opened at $102.75 with a market capitalization of $15.79 billion and a debt-to-equity ratio of 0.66.
• The company reported $1.19 earnings per share for the last quarter, surpassing analysts' expectations by $0.17, although its revenue of $1.06 billion was below the predicted $1.12 billion.

NorthCrest Asset Manangement LLC acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 4,871 shares of the life sciences company's stock, valued at approximately $491,000.

Other institutional investors have also added to or reduced their stakes in the company. Rise Advisors LLC increased its stake in Illumina by 173.6% in the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company's stock valued at $28,000 after purchasing an additional 224 shares during the last quarter. Rakuten Securities Inc. increased its holdings in shares of Illumina by 290.3% during the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock valued at $29,000 after purchasing an additional 270 shares during the period. Center for Financial Planning Inc. acquired a new position in Illumina in the 1st quarter worth approximately $33,000. Fourth Dimension Wealth LLC bought a new position in shares of Illumina in the 4th quarter valued at approximately $40,000. Finally, PFS Partners LLC increased its position in shares of Illumina by 400.0% during the first quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock valued at $40,000 after purchasing an additional 400 shares during the period. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Trading Down 0.3%

NASDAQ:ILMN traded down $0.28 during trading hours on Friday, reaching $102.75. The company's stock had a trading volume of 3,621,712 shares, compared to its average volume of 1,392,780. The firm has a 50-day simple moving average of $99.78 and a 200-day simple moving average of $89.09. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. The firm has a market capitalization of $15.79 billion, a price-to-earnings ratio of 13.01, a PEG ratio of 2.31 and a beta of 1.43.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The business had revenue of $1.06 billion for the quarter, compared to analysts' expectations of $1.12 billion. During the same period last year, the firm earned $0.36 earnings per share. The business's quarterly revenue was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Research analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have issued reports on ILMN shares. Royal Bank Of Canada set a $124.00 price target on shares of Illumina in a research report on Tuesday, September 2nd. Morgan Stanley upped their price target on shares of Illumina from $100.00 to $105.00 and gave the stock an "equal weight" rating in a research note on Monday, August 4th. Barclays raised their target price on shares of Illumina from $85.00 to $90.00 and gave the company an "underweight" rating in a report on Friday, August 1st. Stephens set a $110.00 target price on Illumina and gave the company an "overweight" rating in a research report on Monday, August 4th. Finally, Citigroup lowered shares of Illumina from a "hold" rating to a "strong sell" rating and dropped their price target for the company from $85.00 to $80.00 in a research note on Wednesday, July 9th. Six equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Illumina presently has a consensus rating of "Hold" and an average target price of $123.06.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.